Plesca M.,Oncological Institute |
Bordea C.,Oncological Institute |
El Houcheimi B.,Oncological Institute |
Ichim E.,Oncological Institute |
Blidaru A.,Oncological Institute
Journal of medicine and life | Year: 2016
Surgical treatment of breast cancer has been marked by a constant evolution since the Halsted radical mastectomy described in the late 19th century has become the current standard Madden radical mastectomy, a breast surgery that involves the ablation of tissue with the axillary lymphatic preserving both pectoral muscles. The purpose of this paper was to present the stages that have marked the evolution of this intervention and to provide an overview of the way breast cancer has been understood and treated in the last century.
Pinton P.,French National Institute for Agricultural Research |
Braicu C.,French National Institute for Agricultural Research |
Braicu C.,Oncological Institute |
Nougayrede J.-P.,French National Institute for Agricultural Research |
And 4 more authors.
Journal of Nutrition | Year: 2010
Deoxynivalenol (DON) is a common mycotoxin that contaminates cereals and their by-products. The gastrointestinal tract is the first physical barrier against ingested food contaminants. DON contributes to the loss of barrier function of the intestine through the decreased expression of claudin-4 protein, a tight junction protein. The mechanism by which DON alters the intestinal barrier function remains poorly characterized. Therefore, we investigated the involvement of mitogen-activated protein kinases (MAPK) in the DON-induced loss of barrier function. We first verified that 30 μmol/L of DON activated MAPK in a highly sensitive porcine intestinal epithelial cell line (IPEC-1). Inhibition of p44/42 extracellular signal-regulated kinase (ERK) phosphorylation, with 0.5 μmol/L of the specific MAPK pharmacological inhibitor U0126 for 2 h, restored the barrier function of the differentiated intestinal epithelial cell monolayers. The restoration of barrier function was evaluated by trans-epithelial electrical resistance measurements and tracer flux paracellular permeability experiments. The U0126 also restored the intestinal expression of claudin-4 protein, thereby demonstrating that MAPK activation is involved in claudin-4 protein expression and claudin-4 is involved in the maintenance of the intestinal epithelial cell barrier function. Further experiments indicated that p44/42 ERK is not involved in the transcriptional regulation of claudin-4. In conclusion, we demonstrated that DON-induced activation of the p44/42 ERK signaling pathway inhibits the expression of claudin-4 protein, which leads to impaired intestinal barrier function. Given the high levels of DON in cereal grains, these observations of impaired barrier function have implications for human and animal health. © 2010 American Society for Nutrition.
Amit M.,Technion - Israel Institute of Technology |
Ilana K.,Tel Aviv Medical Center |
Avraham S.P.,Tel Aviv Medical Center |
Binenbaum Y.,Technion - Israel Institute of Technology |
And 8 more authors.
Head and Neck | Year: 2016
Background The role of human papillomavirus (HPV) infection in oropharyngeal cancer (SCC) is well established. The annual incidence of oropharyngeal SCC in Israel is considerably lower than that in the United States. The purpose of this study was to assess the rate of HPV-related oropharyngeal SCC in Israel. Methods The cohort included patients with oropharyngeal SCC who were treated during 1999 to 2011 in Israel. HPV typing was carried out using reverse hybridization and immunohistochemistry. Results Of the 74 patients analyzed, 25 (33.7%) had detectable HPV DNA. Patients in the HPV-positive group tended to be younger, with a higher rate of nodal metastases, and no history of smoking (p <.02). Conclusion This study demonstrated a rate of HPV-related oropharyngeal SCC in Israel as approximately 3-fold lower than in Western countries. Low exposure to HPV-16, a lower rate of transformation, to cancer or protective genetic factors may contribute to the lower rate of oropharyngeal SCC in Israel. © 2015 Wiley Periodicals, Inc..
Pritchard K.I.,University of Toronto |
Rolski J.,Oncological Institute |
Papai Z.,State Health Center |
Mauriac L.,Institute Bergonie |
And 9 more authors.
Breast Cancer Research and Treatment | Year: 2010
The Faslodex Investigation of Dose evaluation in Estrogen Receptor-positive advanced breast cancer (FINDER)2 study evaluated the efficacy, safety, and pharmacokinetics (PK) of three fulvestrant dosing regimens. FINDER2 enrolled Western postmenopausal women recurring or progressing after prior endocrine therapy. Primary endpoint: objective response rate (ORR); secondary endpoints: time to progression (TTP), clinical benefit rate (CBR), tolerability, and PK parameters. Patients were randomized to receive fulvestrant: 250 mg/month (approved dose [AD]); 250 mg plus loading dose (loading dose [LD]; 500 mg on day 0, 250 mg on days 14, 28, and monthly thereafter); or 500 mg (high dose [HD]; 500 mg/month plus 500 mg on day 14 of Month 1). Treatment continued until disease progression or discontinuation. 144 patients were randomized: fulvestrant AD (n = 47); LD (n = 51); HD (n = 46). ORRs were: 8.5% (95% confidence interval [CI]: 2.4, 20.4%), 5.9% (1.2, 16.2%), and 15.2% (6.3, 28.9%) in the AD, LD, and HD arms, respectively. CBRs were: 31.9% (95% CI: 19.1, 47.1%), 47.1% (32.9, 61.5%), and 47.8% (32.9, 63.1%) for the AD, LD, and HD arms, respectively. Median TTP (months) was numerically longer for HD (6.0) and LD (6.1) versus AD (3.1). Tolerability was similar across dosing regimens. Steady-state plasma fulvestrant concentrations were predictable and achieved earlier with LD and HD. While there appeared to be a trend toward improved efficacy with HD and LD versus AD, no significant differences could be shown. A parallel study (FINDER1) has reported similar findings in Japanese patients. © 2010 Springer Science+Business Media, LLC.
Marichalar-Mendia X.,University of the Basque Country |
Acha-Sagredo A.,University of the Basque Country |
Rodriguez-Tojo M.J.,University of the Basque Country |
Rey-Barja N.,University of the Basque Country |
And 3 more authors.
Anticancer Research | Year: 2011
Oral and laryngeal cancer has a high incidence in the Basque Country (Spain), the main risk factors in this pathology being regular consumption of tobacco and alcohol. However, since not all the individuals exposed to these risk factors develop cancer, the individual genetic susceptibility should be investigated in this population. The aim of this study was to determine the distribution of alcohol dehydrogenase-1B polymorphism (Arg48His; rs1229984) in our region and analyze its association with the risk of oral and laryngeal squamous cell carcinoma. Samples from 87 patients with oral or laryngeal cancer and 242 healthy controls were analyzed. Multivariate logistic regression analysis showed that the combined Arg/His and His/His genotypes were associated with a reduced risk of head and neck squamous cell carcinoma (odds ratio: 0.203; 95% confidence interval: 0.052-0.796). In conclusion, the histidine allele was associated with a reduced risk of oral and laryngeal cancer in the Basque Country.
Koensgen D.,University of Greifswald |
Bruennert D.,University of Greifswald |
Ungureanu S.,University of Greifswald |
Ungureanu S.,Oncological Institute |
And 12 more authors.
Cytokine | Year: 2015
Ovarian cancer still represents a challenge in gynecological oncology. Most patients are diagnosed in an advanced tumor stage. No specific screening or prevention strategies for ovarian cancer exist as of yet.Interleukin 8 (IL-8) is a pro-inflammatory chemokine known for its angiogenetic activity, and is supposedly responsible for tumor-associated angiogenesis in several malignant tumors.The aim of the study was to investigate the susceptibility of patients with an IL-8 gene polymorphism to developing ovarian cancer.Four single nucleotide polymorphisms (SNPs) (IL-8 -251, IL-8 +781, IL-8 +1633 and IL-8 +2767) of the IL-8 gene were screened, using the PCR method in 268 patients with ovarian cancer and 426 healthy women as a control group. Significant associations were noted in patients with the IL-8 +781 (T/T) genotype (. p=. 0.0048) with increased frequencies of ovarian cancer, while women with the IL-8 +781 (C/C) allele suffer from ovarian cancer significantly less frequently (. p=. 0.0003). Furthermore, the IL-8 +2767 (T/T) genotype is also associated with a higher risk of ovarian cancer (. p=. 0.0177).Our results indicate, for the first time, that IL-8 polymorphism is associated with ovarian cancer. © 2014 Elsevier Ltd.
PubMed | Institute for Biometrics and Medical Informatics, Oncological Institute, Charité - Medical University of Berlin, Epiontis GmbH and 2 more.
Type: Journal Article | Journal: Cytokine | Year: 2015
Ovarian cancer still represents a challenge in gynecological oncology. Most patients are diagnosed in an advanced tumor stage. No specific screening or prevention strategies for ovarian cancer exist as of yet. Interleukin 8 (IL-8) is a pro-inflammatory chemokine known for its angiogenetic activity, and is supposedly responsible for tumor-associated angiogenesis in several malignant tumors. The aim of the study was to investigate the susceptibility of patients with an IL-8 gene polymorphism to developing ovarian cancer. Four single nucleotide polymorphisms (SNPs) (IL-8 -251, IL-8 +781, IL-8 +1633 and IL-8 +2767) of the IL-8 gene were screened, using the PCR method in 268 patients with ovarian cancer and 426 healthy women as a control group. Significant associations were noted in patients with the IL-8 +781 (T/T) genotype (p=0.0048) with increased frequencies of ovarian cancer, while women with the IL-8 +781 (C/C) allele suffer from ovarian cancer significantly less frequently (p=0.0003). Furthermore, the IL-8 +2767 (T/T) genotype is also associated with a higher risk of ovarian cancer (p=0.0177). Our results indicate, for the first time, that IL-8 polymorphism is associated with ovarian cancer.
Netzer I.,Gynecological Oncology Unit |
Sobeh S.,Technion - Israel Institute of Technology |
Keidar Z.,Technion - Israel Institute of Technology |
Keidar Z.,Rambam Health Care Campus |
And 6 more authors.
Medical Oncology | Year: 2013
Cervical cancer is one of the leading causes of death among women with gynecological malignancies. In early stages of the disease (IB-IIA), surgical treatment alone is usually the treatment of choice. However, some high-risk patients are referred for postoperative chemo-radiotherapy, leading to increased morbidity. Maximal Standardized Uptake Value (SUVmax) is a positron emission tomography-computed tomography (PET-CT)-derived semiquantitative measurement of fluorodeoxyglucose (FDG) uptake in a defined lesion and may reflect tumor aggressiveness. The purpose of this study was to determine whether preoperative high SUVmax values can be used for the selection of initial therapy, thus reducing the side effects resulting from bimodal treatment. PET-CT studies of 46 cervical cancer patients who underwent surgery were reviewed, and SUVmax data were collected. Statistical analyses were performed to determine the relationships between SUVmax values and clinical parameters, modalities of treatment, and outcomes. SUV max was found to correlate with depth of tumor invasion (r = 0.46, p < 0.003). A statistically significant correlation was also found between SUVmax and histological grade, with the mean and variance of SUV max significantly lower for grade one, as compared to grades two and three (mean 1.10, 11.06, and 8.88; variance 3.57, 45.60, and 29.79, respectively; p < 0.0001 and p = 0.076). A possible SUVmax cutoff value of 10.08 was identified as a potential indicator of increased risk for receiving bimodal treatment, with a sensitivity of 61.5 % and a specificity of 75.8 %. SUVmax can be used for differentiating early-stage cervical cancer patients who will need postoperative adjuvant treatment and therefore can serve as an additional modality to reduce the need for bimodal therapy in these patients. © 2013 Springer Science+Business Media New York.
Grigore M.,Grigore T. Popa University of Medicine and Pharmacy |
Ilea C.,Grigore T. Popa University of Medicine and Pharmacy |
Terinte C.,Oncological Institute |
Sava A.,Grigore T. Popa University of Medicine and Pharmacy |
Popovici R.,Grigore T. Popa University of Medicine and Pharmacy
European Journal of Gynaecological Oncology | Year: 2014
Carcinosarcoma is a rare, extremely aggressive tumor of the uterus with a poor prognosis. The authors describe a case of a 78-year-old woman who presented with a giant mass protruding through the cervix, vagina, and vulva. A total abdominal hysterectomy with bilateral salpingo-oophorectomy was performed. The histopathological examination of the surgical specimen revealed a malignant mixed Müllerian tumor. The clinical and pathological features, molecular data, and prognosis of this aggressive neoplasm are discussed. Although uterine carcinosarcomas are extremely rare, when a postmenopausal woman with a vulvar mass is admitted to the gynecology clinic, the physician should consider that the mass may be a carcinosarcoma.
PubMed | Oncological Institute and Cluj Napoca County Hospital
Type: Journal Article | Journal: Journal of surgical case reports | Year: 2015
Liposarcomas are neoplasms of mesodermic origin, are derived from adipose tissue and represent <1% of all malignant tumours. Primary liposarcomas of the kidney are very rare. Here, we present the cases of two patients diagnosed with retroperitoneal perirenal myxoid liposarcoma. The patients were diagnosed via imaging, which in both cases revealed a huge right retroperitoneal tumour mass compressing the abdominal organs and large blood vessels. Surgical intervention consisting of en bloc resection of the tumour and the right kidney was performed using a transperitoneal approach. Three years after the surgery, both patients presented local recurrence, for which they underwent chemotherapy. Liposarcomas with renal origin are rare clinical entities with a high rate of malignancy and a poor prognosis. Because the use of chemotherapy and radiotherapy in the treatment of such liposarcomas is controversial, the treatment of choice is wide surgical resection with clean margins.